EPRX
Eupraxia Pharmaceuticals Inc.
6.71
1 x 6.66
1 x 6.66
bid
ask
+
0.10
1.51%
1 @ 08:33 AM
6.99 +0.28 (4.17%)
| Ytd | -11.13% | |
| 1y | 14.90% |
6.10
day range
6.86
4.88
52 week range
9.32
| Open | 6.63 | Prev Close | 6.61 | Low | 6.10 | High | 6.86 | Mkt Cap | 438.34M |
| Vol | 259.98K | Avg Vol | 285.43K | EPS | -1.05 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.23 | Short Ratio | 27.74 | Inst. Own | 12.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 6.83 | 200-d Avg | 6.94 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 15.96M | ||
| Research and Development Expense | 11.17M | ||
| Selling, General and Administrative Expense | 4.78M | ||
| Operating Income | -15.96M | ||
| Income Tax Expense | 13.91K | ||
| Net Income | -12.65M | ||
| Net Income Common Stock | -12.65M | ||
| Net Income Common Stock (USD) | -12.65M | ||
| Consolidated Income | -12.65M | ||
| Net Income to Non-Controlling Interests | 1.42K | ||
| Earnings per Basic Share | -0.23 | ||
| Earnings per Basic Share (USD) | -0.23 | ||
| Earnings per Diluted Share | -0.23 | ||
| Earning Before Interest & Taxes (EBIT) | -12.64M | ||
| Earning Before Interest & Taxes (USD) | -12.64M | ||
| Weighted Average Shares | 56.71M | ||
| Weighted Average Shares Diluted | 56.71M | ||
| Balance Sheet | |||
| Cash and Equivalents | 58.50M | ||
| Cash and Equivalents (USD) | 58.50M | ||
| Investments | 80.38M | ||
| Investments Current | 80.38M | ||
| Trade and Non-Trade Receivables | 663.24K | ||
| Current Assets | 142.13M | ||
| Property, Plant & Equipment Net | 3.17M | ||
| Total Assets | 145.35M | ||
| Debt Current | 203.51K | ||
| Total Debt | 2.01M | ||
| Current Liabilities | 7.36M | ||
| Debt Non-Current | 1.80M | ||
| Total Liabilities | 9.17M | ||
| Accumulated Retained Earnings (Deficit) | -182.23M | ||
| Accumulated Other Comprehensive Income | -4.48M | ||
| Shareholders Equity | 137.78M | ||
| Shareholders Equity (USD) | 137.78M | ||
| Assets Non-Current | 3.23M | ||
| Total Debt (USD) | 2.01M | ||
| Liabilities Non-Current | 1.80M | ||
| Trade and Non-Trade Payables | 7.16M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 68.58M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -21.62M | ||
| Capital Expenditure | -326.95K | ||
| Issuance (Purchase) of Equity Shares | 68.58M | ||
| Net Cash Flow from Investing | -80.05M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -79.72M | ||
| Net Cash Flow from Operations | -10.15M | ||
| Effect of Exchange Rate Changes on Cash | -448.18K | ||
| Share Based Compensation | 2.25M | ||